Xenetic Biosciences (NASDAQ:XBIO) Announces Quarterly Earnings Results, Misses Expectations By $0.48 EPS

Xenetic Biosciences (NASDAQ:XBIO) posted its quarterly earnings data on Tuesday. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.48), Zacks reports. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%.

Xenetic Biosciences Trading Down 5.7 %

Shares of XBIO traded down $0.21 during trading hours on Tuesday, reaching $3.46. 13,751 shares of the company traded hands, compared to its average volume of 12,669. The firm has a market cap of $5.34 million, a price-to-earnings ratio of -1.30 and a beta of 2.17. Xenetic Biosciences has a 12-month low of $2.78 and a 12-month high of $5.20. The stock’s fifty day moving average price is $4.03 and its 200 day moving average price is $4.01.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a research report on Thursday, December 5th.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.